IQVIA (NYSE:IQV) Lifted to "Buy" at StockNews.com

StockNews.com upgraded shares of IQVIA (NYSE:IQV - Free Report) from a hold rating to a buy rating in a report published on Saturday.

A number of other analysts have also issued reports on the company. The Goldman Sachs Group started coverage on IQVIA in a research note on Thursday, June 6th. They issued a buy rating and a $270.00 price target on the stock. Robert W. Baird lowered their price target on IQVIA from $254.00 to $245.00 and set a neutral rating on the stock in a research note on Friday, May 3rd. Truist Financial lowered their price target on IQVIA from $297.00 to $292.00 and set a buy rating on the stock in a research note on Friday, May 3rd. Barclays lowered their price target on IQVIA from $275.00 to $255.00 and set an overweight rating on the stock in a research note on Friday. Finally, Evercore ISI lowered their price target on IQVIA from $275.00 to $250.00 and set an outperform rating on the stock in a research note on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus target price of $257.73.

IQVIA Stock Performance

IQV stock traded down $1.31 during trading on Friday, hitting $211.44. 5,448,174 shares of the company traded hands, compared to its average volume of 1,310,028. The stock's 50-day simple moving average is $223.93 and its 200 day simple moving average is $230.15. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88. The company has a market cap of $38.52 billion, a PE ratio of 28.89, a P/E/G ratio of 1.94 and a beta of 1.53. IQVIA has a 1 year low of $167.42 and a 1 year high of $261.73.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, beating analysts' consensus estimates of $2.19 by $0.11. The business had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. On average, equities analysts expect that IQVIA will post 10.11 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Several institutional investors and hedge funds have recently modified their holdings of the company. Team Hewins LLC raised its holdings in shares of IQVIA by 5.0% in the 1st quarter. Team Hewins LLC now owns 973 shares of the medical research company's stock valued at $246,000 after buying an additional 46 shares during the period. Covestor Ltd raised its holdings in shares of IQVIA by 45.3% in the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company's stock valued at $39,000 after buying an additional 48 shares during the period. Jag Capital Management LLC boosted its position in shares of IQVIA by 0.4% during the 4th quarter. Jag Capital Management LLC now owns 11,401 shares of the medical research company's stock worth $2,638,000 after acquiring an additional 49 shares in the last quarter. Laurel Wealth Advisors LLC boosted its position in shares of IQVIA by 1.1% during the 3rd quarter. Laurel Wealth Advisors LLC now owns 4,710 shares of the medical research company's stock worth $927,000 after acquiring an additional 50 shares in the last quarter. Finally, Raleigh Capital Management Inc. boosted its position in shares of IQVIA by 4.5% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,157 shares of the medical research company's stock worth $268,000 after acquiring an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.